The increase in price target by JMP Securities reflects a positive outlook on Acrivon Therapeutics' stock, likely due to anticipated performance improvements or positive developments within the company. This analyst action can positively influence investor sentiment and potentially lead to a short-term increase in stock price, as market participants may view the revised price target as a strong endorsement of the company's future prospects.